Brachytherapy (Plaque Radiotherapy)
Treatment for Retinoblastoma
Typical Dosage: 40-50 Gy to tumor apex
Effectiveness
88%
Safety Score
30%
Clinical Trials
3
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
40-50 Gy to tumor apex
Time to Effect
1-3 months
Treatment Duration
3-7 days (plaque implantation)
Evidence Quality
HIGHConfidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$40,000
Side Effect Mgmt:$5,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
18
Outcome-Based Costs
Cost per Responder
$50,000
Cost per Remission
$52,941
Comparison vs Systemic Chemotherapy
Cost Difference
$-30,000/year
Less expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Brachytherapy (Plaque Radiotherapy) Outcomes
for Retinoblastoma
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Cataract
+50%
Radiation retinopathy/optic neuropathy
+30%
Vitreous hemorrhage
+15%
Retinal detachment
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Brachytherapy (Plaque Radiotherapy) in Retinoblastoma
Retinoblastoma Consolidation in Egyptians
NCT07530458NOT YET RECRUITING
150 participants
OBSERVATIONAL
Started: May 1, 2026
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
NCT01783535ACTIVE NOT RECRUITINGPHASE2
174 participants
INTERVENTIONAL
Memphis, United States
Started: Jun 19, 2013
Completed Clinical Trials
2 completed trials for Brachytherapy (Plaque Radiotherapy) in Retinoblastoma
Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma
NCT02792036COMPLETEDPHASE1
8 participants
INTERVENTIONAL
Memphis, United States
Started: Nov 1, 2016
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
NCT00186888COMPLETEDPHASE3
107 participants
INTERVENTIONAL
Memphis, United States
Started: Apr 7, 2005